Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IV Infiltration Clear all
Active, not recruiting Phase 1 Interventional

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

NCT05176470
View directory record Official record
Conditions
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Stage IV Melanoma
Interventions
Cyclophosphamide, Fludarabine, Lifileucel, Pembrolizumab, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
Richard Wu
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Interventions
IOV-3001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1 Interventional Results available

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

NCT03215810
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
Interventions
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2)
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

NCT01807182
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Metastatic Melanoma
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Therapeutic Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ivWatch Model 400: Device Validation for Infiltrated Tissues

NCT02123745
View directory record Official record
Conditions
Infiltration of Peripheral IV Therapy
Interventions
The ivWatch Model 400
Device
Lead sponsor
ivWatch, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Williamsburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

NCT00062036
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, incomplete Freund's adjuvant, interleukin-2 gene, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 2:48 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2)
Biological · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ivWatch Model 400: Device Validation for Non-Infiltrated Tissues

NCT02120443
View directory record Official record
Conditions
Infiltration of Peripheral IV Therapy
Interventions
ivWatch Model 400
Device
Lead sponsor
ivWatch, LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Williamsburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Jul 22, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00182793
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Detection of Peripheral IV Infiltration

NCT01800552
View directory record Official record
Conditions
Infiltration, IV Infiltration
Interventions
Intentional infiltration of a peripheral IV site
Procedure
Lead sponsor
ivWatch, LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Williamsburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jul 22, 2026, 2:48 PM EDT
Completed No phase listed Observational

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01706432
View directory record Official record
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 22, 2026, 2:48 PM EDT